Skip to content
Open access · CC-BY via OpenAlex

Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities

Carolina Sandoval-Caballero, Zander Roemer, Catherine M. Kotz, Michael A. Puskarich, Vijayakumar Mavanji, Elizabeth L. Schmidt, Shalamar Dionne Sibley

Nutrients · 2026

Abstract

Fisetin, a naturally occurring flavonoid, has garnered interest as a potential intervention for age-related diseases due to its anti-inflammatory, antioxidant, and senolytic properties, as demonstrated primarily in preclinical studies. We conducted a structured search and evaluated human translational and clinical studies that utilize fisetin to improve clinical markers associated with age-related low-grade inflammatory diseases. Building on preclinical work and observational studies in humans consuming flavonoid-rich diets or supplements, we evaluated 34 registered clinical trials on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) with a focus on aging/frailty, metabolic diseases, cancer, cardiovascular diseases, neuroimmune/neurodegenerative diseases, and other chronic age-related diseases. We provide the status of the 34 registered trials and a synthesis and discussion of the 4 completed trials with available results that included fisetin, identifying gaps and areas for future investigation. Overall, the completed trials indicate that clinical evidence for fisetin remains limited and heterogeneous. While some studies reported favorable changes in metabolic or inflammatory outcomes, others found no clear or significant clinical benefit. Interpretation is further limited by small sample sizes, multimodal interventions, and uncontrolled or exploratory designs, making it difficult to establish fisetin efficacy in humans. Early findings in animal models and in human cell lines suggest that fisetin has the potential to mitigate age-related diseases by targeting chronic inflammation and oxidative stress driven by increased senescent cell burden, but more clinical data are needed.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3390/nu18182999
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Sandoval-Caballero, C., Roemer, Z., Kotz, C.M., Puskarich, M.A., Mavanji, V., Schmidt, E.L., &amp; Sibley, S.D. (2026). Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities. <em>Nutrients</em>. https://doi.org/10.3390/nu18182999
Vancouver
Sandoval-Caballero C, Roemer Z, Kotz CM, Puskarich MA, Mavanji V, Schmidt EL, et al. Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities. Nutrients. 2026. doi:10.3390/nu18182999.
BibTeX
@article{carolina2026Clinic, title = {Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities}, author = {Carolina Sandoval-Caballero and Zander Roemer and Catherine M. Kotz and Michael A. Puskarich and Vijayakumar Mavanji and Elizabeth L. Schmidt and Shalamar Dionne Sibley}, journal = {Nutrients}, year = {2026}, doi = {10.3390/nu18182999}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings